Crystal structures of protease-activated receptor 2 (PAR2) in complex with two different antagonist ligands and with a blocking antibody reveal binding sites that are distinct from those found on PAR1, offering new leads for structure-based drug design.
- Robert K. Y. Cheng
- Cédric Fiez-Vandal
- Niek Dekker